RET-PTC2
Showing 1 - 25 of 755
RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Worldwide
Active, not recruiting
- RET-altered Non Small Cell Lung Cancer
- +39 more
- pralsetinib (BLU-667)
-
Phoenix, Arizona
- +65 more
Nov 10, 2022
Thyroid Cancer, Thyroid Carcinoma, Metastatic Thyroid Cancer Trial in Boston (Selpercatinib, Sodium Iodine I-131, rhTSH)
Not yet recruiting
- Thyroid Cancer
- +5 more
- Selpercatinib
- +2 more
-
Boston, MassachusettsMassachusetts General Hospital
Dec 20, 2022
Solid Tumor, Medullary Thyroid Cancer Trial in China (Selpercatinib)
Active, not recruiting
- Solid Tumor
- Medullary Thyroid Cancer
-
Guangzhou, Guangdong, China
- +12 more
May 9, 2022
Refractory Solid Tumors Trial in Seoul (sunitinib)
Completed
- Refractory Solid Tumors
-
Seoul, Korea, Republic ofSamsung Medical Center
Jun 13, 2022
ALK-positive NSCLC (NSCLC), RET-positive NSCLC (NSCLC), RET-positive Thyroid Cancer Trial in Irvine, Boston (Alectinib)
Terminated
- ALK-positive Non-small Cell Lung Cancer (NSCLC)
- +2 more
-
Irvine, California
- +3 more
Aug 30, 2021
Lung Cancer, Non Small Cell Lung Cancer Trial in Aurora (Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined))
Not yet recruiting
- Lung Cancer
- Non Small Cell Lung Cancer
- Amivantamab 1050mg
- +2 more
-
Aurora, Colorado
- +2 more
Apr 25, 2023
Nonsene Mutation Duchenne Muscular Dystrophy Trial in Atlanta (Ataluren)
Recruiting
- Nonsene Mutation Duchenne Muscular Dystrophy
-
Atlanta, GeorgiaRare Disease Research, LLC
Jan 27, 2023
HER2-negative Early Breast Cancer Trial in Beijing (neoadjuvant chemo upon in vitro PTC drug sensitivity screening for triple
Recruiting
- HER2-negative Early Breast Cancer
- neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for triple negative breast cancer
- neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for luminal like breast cancer
-
Beijing, ChinaPeking University People's Hospital
Mar 27, 2022
NSCLC, RET Driver Mutation, BRAF V600 Mutation Trial in Guanzhou (Toripalimab, Nab paclitaxel, Pemetrexed)
Recruiting
- Non-Small Cell Lung Cancer
- +5 more
- Toripalimab
- +3 more
-
Guanzhou, Guangdong, ChinaGuangdong Lung Cancer Institute, Guangdong Provincial People's H
Apr 4, 2023
Advanced Malignant Tumor, Metastatic Malignant Tumor, Recurrent Malignant Tumor Trial in Houston (Everolimus, Laboratory
Recruiting
- Advanced Malignant Neoplasm
- +3 more
- Everolimus
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Dec 9, 2022
Epilepsy Trial in New York (ataluren, Placebo)
Completed
- Epilepsy
- ataluren
- Placebo
-
New York, New YorkNew York University School of Medicine
Sep 7, 2021
Sarcopenia, Muscle Atrophy, Osteoporosis Trial in Birmingham (RET, Placebo, Vitamin D3)
Completed
- Sarcopenia
- +2 more
- RET
- +2 more
-
Birmingham, United KingdomUniversity of Birmingham
Feb 7, 2022
Duchenne Muscular Dystrophy Trial in Los Angeles (Ataluren)
Completed
- Duchenne Muscular Dystrophy
-
Los Angeles, CaliforniaUniversity of California, Los Angeles (UCLA)
Mar 9, 2022
Laparoscopic Colorectal Surgeries Trial in Montréal-Est (Rocuronium IV bolus 0.1 mg/kg guided by TOF that must remain between
Recruiting
- Laparoscopic Colorectal Surgeries
- Rocuronium IV bolus 0.1 mg/kg guided by TOF that must remain between 1-3 during surgery
- Rocuronium IV bolus 0.1 mg/kg guided by TOF 0/4 and PTC≤ 2
-
Montréal-Est, Quebec, CanadaHopital Maisonneuve Rosemont, CIUSSS de l'Est de l'Ile de Montré
Apr 4, 2022
Nonsmall Cell Lung Cancer Trial in Shanghai (HS-10365 capsules)
Recruiting
- Nonsmall Cell Lung Cancer
- HS-10365 capsules
-
Shanghai, Shanghai, ChinaShanghai Chest Hospital
Nov 22, 2023
RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Chang chun
Not yet recruiting
- RET-altered Non Small Cell Lung Cancer
- +3 more
-
Chang chun, Jilin, ChinaJinlin Province Cancer Hosipital
Dec 21, 2022
Hematopoietic and Lymphoid Cell Tumor, Recurrent Ependymoma, Recurrent Ewing Sarcoma Trial in Puerto Rico, United States
Recruiting
- Hematopoietic and Lymphoid Cell Neoplasm
- +37 more
-
Birmingham, Alabama
- +171 more
Aug 24, 2022
Medullary Thyroid Cancer Trial in Worldwide (Selpercatinib, Cabozantinib, Vandetanib)
Recruiting
- Medullary Thyroid Cancer
- Selpercatinib
- +2 more
-
Birmingham, Alabama
- +148 more
Jan 18, 2023